HBM Holdings Limited (2142.HK) HKSE
13.99
-0.15(-1.06%)
Currency In HKD
- General
- Statistics
- Historical Data
- Profile
- Financials
13.99
-0.15(-1.06%)
Currency In HKD
Address
Tower A, 12th Floor
Shanghai, 200032
China
Phone
86 21 5339 9123
Sector
Healthcare
Industry
Biotechnology
Employees
183
First IPO Date
December 10, 2020
| Name | Title | Pay | Year Born |
| Jingsong Wang | Founder, Chairman & Chief Executive Officer | 8.36M | 1965 |
| Yiping Rong | Chief Scientific Officer & Executive Director | 3.2M | 1977 |
| Ben Chih | Chief Scientific Officer of Neurosciences - Harbour BioMed US | 0 | N/A |
| Ian Y. Liu | Senior VP & Global Head of Legal and Joint Company Secretary | 0 | N/A |
| Peter F. Moesta | Member of Scientific Advisory Board & Chief CMC Advisor | 0 | N/A |
| Raymond S. Zheng | Chief Business Officer | 0 | N/A |
| Steve Arkinstall DPhil | Chief Scientific Advisor | 0 | N/A |
| Xiaolu Tao | Chief Development Officer | 0 | 1975 |
| Michael D. Patten | Chief Strategy Officer & Head of Global Alliance | 0 | N/A |
| Youchen Chen | Vice President, Chief Financial Officer & Investor Relations | 0 | N/A |
HBM Holdings Limited, a clinical-stage biopharmaceutical company, engages in the discovery and development of differentiated antibody therapeutics in immunology and oncology disease areas. It is developing Batoclimab (HBM9161), a human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor; Tanfanercept (HBM9036) to treat moderate to-severe dry eye disease; HBM7008, a bispecific antibody targeting tumor Associated antigen; and HBM4003, a human anti-CTLA-4 antibody against cytotoxic T-lymphocyte-associated antigen-4. The company is also developing HBM9022 for the treatment of SARS-COV-2; HBM9302 for the treatment of breast and gastric cancers; HBM7020 for the treatment of multiple myeloma; and HBM1007, HBM1029, HBM7015, HBM7008, and HBM1022 for the treatment of solid tumors. It operates in Mainland China, the United States, Europe, and internationally. The company has collaboration on antibody-drug conjugate projects with LegoChem Biosciences Inc. and Duality Biotherapeutics, Inc. HBM Holdings Limited was incorporated in 2016 and is based in Shanghai, the People's Republic of China.